Literature DB >> 2431055

Multiple overlapping epitopes in the three antigenic regions of horse cytochrome c1.

R Jemmerson.   

Abstract

To gain a better understanding of the diversity of epitopes on a protein, the specificities of 103 monoclonal antibodies to a model antigen, horse cytochrome c(cyt c), were analyzed. The antibodies were generated in in vitro monoclonal, secondary antibody responses against horse cyt c coupled to hemocyanin in splenic fragment cultures. For this assay, horse cyt c-primed murine B lymphocytes were transferred to irradiated, hemocyanin-primed recipients. A panel of seven mammalian cyts c differing at one to six residues out of 104 and cyanogen bromide-cleaved fragments of horse cyt c containing residues 1-65, 1-80, and 66-104 was used to examine the specificities of the antibodies. Twenty-two distinct reactivity patterns were observed, even though the majority of the monoclonal antibodies were found to bind in the three previously identified antigenic regions of the molecule about residues 44-47, 60-62, and 89-92. The results indicate that each of the three antigenic regions consists of multiple overlapping epitopes. Few of the antibodies directed to any given antigenic region bound polypeptide fragments inclusive of the epitope sequences, demonstrating that some antibodies were more conformationally dependent than others. Only 13% of the antibodies bound to cyanogen bromide-cleaved polypeptide fragments that together encompassed the entire length of the protein. Considering the large number of antibodies analyzed and the reoccurrence of 13 of the 22 clonotypes in different lymphocyte donors, it is likely that the antibody specificities tabulated herein approach yet do not completely enumerate the total inventory of the horse cyt c-specific B cell repertoire. The remarkable diversity for epitope recognition within antigenic regions observed here is likely to pertain to protein antigens in general, and strongly supports the widely held notion that the entire surface of a protein is potentially antigenic. The restriction of the epitopes of horse cyt c to three antigenic regions where the amino acid sequences of the mammalian cyts c differ probably results from tolerance of the mice to their own cyt c.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2431055

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Antigenicity and native structure of globular proteins: low frequency of peptide reactive antibodies.

Authors:  R Jemmerson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Isolation of cell surface antigen mutants of Myxococcus xanthus by use of monoclonal antibodies.

Authors:  J M Fink; M Kalos; J F Zissler
Journal:  J Bacteriol       Date:  1989-04       Impact factor: 3.490

Review 3.  Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.

Authors:  Satoshi Nagata; Ira Pastan
Journal:  Adv Drug Deliv Rev       Date:  2009-08-11       Impact factor: 15.470

4.  Reaction of rheumatoid factors with IgG3 monoclonal anti-Rh(D) antibodies: more frequent reactivity to a monoclonal antibody of the Gm allotype G3m(5) in rheumatoid patients negative for G3m(5).

Authors:  A H Puttick; E A Williamson; A H Merry; B M Kumpel; K M Thompson; V E Jones
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

5.  A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm.

Authors:  Pascal Philibert; Audrey Stoessel; Wei Wang; Annie-Paule Sibler; Nicole Bec; Christian Larroque; Jeffery G Saven; Jérôme Courtête; Etienne Weiss; Pierre Martineau
Journal:  BMC Biotechnol       Date:  2007-11-22       Impact factor: 2.563

6.  Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.

Authors:  Joerg U Schmohl; Deborah Todhunter; Seung Oh; Daniel A Vallera
Journal:  Toxins (Basel)       Date:  2015-10-10       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.